WO2012060786A3 - Cefpodoxime proxetil formulations comprising viscosity agent - Google Patents

Cefpodoxime proxetil formulations comprising viscosity agent Download PDF

Info

Publication number
WO2012060786A3
WO2012060786A3 PCT/TR2011/000251 TR2011000251W WO2012060786A3 WO 2012060786 A3 WO2012060786 A3 WO 2012060786A3 TR 2011000251 W TR2011000251 W TR 2011000251W WO 2012060786 A3 WO2012060786 A3 WO 2012060786A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
cefpodoxime proxetil
viscosity agent
proxetil
cefpodoxime
Prior art date
Application number
PCT/TR2011/000251
Other languages
French (fr)
Other versions
WO2012060786A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012060786A2 publication Critical patent/WO2012060786A2/en
Publication of WO2012060786A3 publication Critical patent/WO2012060786A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.
PCT/TR2011/000251 2010-11-05 2011-11-03 Cefpodoxime proxetil formulations comprising viscosity agent WO2012060786A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09168 2010-11-05
TR2010/09168A TR201009168A2 (en) 2010-11-05 2010-11-05 Water dispersible cefpodoxime proxetil formulations.

Publications (2)

Publication Number Publication Date
WO2012060786A2 WO2012060786A2 (en) 2012-05-10
WO2012060786A3 true WO2012060786A3 (en) 2012-07-26

Family

ID=45446166

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000255 WO2012060790A2 (en) 2010-11-05 2011-11-03 Water dispersible cefpodoxime proxetil formulations
PCT/TR2011/000251 WO2012060786A2 (en) 2010-11-05 2011-11-03 Cefpodoxime proxetil formulations comprising viscosity agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000255 WO2012060790A2 (en) 2010-11-05 2011-11-03 Water dispersible cefpodoxime proxetil formulations

Country Status (2)

Country Link
TR (1) TR201009168A2 (en)
WO (2) WO2012060790A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151517A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Tablet formulations comprising cefpodoxime proxetil and clavulanic acid
CN103142506B (en) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof
CN103230367B (en) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 Cefpodoxime proxetil composition dry suspension and preparation method thereof
BR112017011591A2 (en) * 2014-12-01 2018-03-06 Sun Pharmaceutical Ind Ltd stable extended release composition, process for preparing the extended release composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
JP2004043475A (en) * 2002-07-08 2004-02-12 Sankyo Co Ltd Oral cephalosporin preparation
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2011129792A1 (en) * 2010-04-13 2011-10-20 Mahmut Bilgic Water dispersible formulations comprising cefpodoxime proxetil

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
KR20050062514A (en) * 2002-07-16 2005-06-23 랜박시 래보러터리스 리미티드 Dispersible tablets for oral administration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
JP2004043475A (en) * 2002-07-08 2004-02-12 Sankyo Co Ltd Oral cephalosporin preparation
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2011129792A1 (en) * 2010-04-13 2011-10-20 Mahmut Bilgic Water dispersible formulations comprising cefpodoxime proxetil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200416, Derwent World Patents Index; AN 2004-169094, XP002676813 *

Also Published As

Publication number Publication date
WO2012060786A2 (en) 2012-05-10
WO2012060790A3 (en) 2012-09-20
TR201009168A2 (en) 2012-05-21
WO2012060790A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
JOP20180102B1 (en) Pharmaceutical composition
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
MX2013002264A (en) Pesticidal compositions.
WO2011093824A3 (en) Effervescent formulations comprising cefaclor
WO2012009723A8 (en) C-met modulator pharmaceutical compositions
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
HK1164304A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2011084848A3 (en) Prodrugs of heteraromatic compounds
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
WO2010119455A3 (en) An injectable sustained release pharmaceutical composition
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2013190274A3 (en) Biodegradable compositions
WO2012060786A3 (en) Cefpodoxime proxetil formulations comprising viscosity agent
WO2012080176A3 (en) Pharmaceutical compositions comprising alisporivir
WO2012026907A3 (en) Cefpodoxime proxetil formulations
WO2012051126A3 (en) Anti-inflammatory macrolides
WO2012042540A9 (en) Anticancer agent
TR201002878A2 (en) Pharmaceutical compositions comprising cefpodoxime proxetil.
WO2012007570A3 (en) New formulations of 14-epi-analogues of vitamin d
IT1399492B1 (en) EFFERVESCENT PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYLCISTEIN.
WO2012004073A3 (en) Use of beta-isophorone as solvent
WO2011152805A3 (en) Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid
CA2865491A1 (en) Spray dried formulations
BR112013016029A2 (en) phosphomycin pharmaceutical composition.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805268

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11805268

Country of ref document: EP

Kind code of ref document: A2